Lv4
558 积分 2024-08-22 加入
Discovery and Mechanism of 16–19F, a Novel Synthetic Lethal Inhibitor of the PRMT5•MTA Complex in MTAP-Deleted Cancer Cells
15天前
已完结
Discovery of Potent, Highly Selective, and Orally Bioavailable MTA Cooperative PRMT5 Inhibitors with Robust In Vivo Antitumor Activity
16天前
已完结
Drug discovery targeting protein arginine methyltransferase 5 (PRMT5): an update
16天前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
16天前
已完结
Discovery of TNG-6132, a potent, selective, and orally bioavailable USP1 inhibitor
1个月前
已完结
Rituximab-Chidamide combination chemotherapy enhances autophagy to overcome drug resistance in diffuse large B-cell lymphoma
1个月前
已完结
P3.12D.10 Phase 1b Study of AMG 193, An MTA-Cooperative PRMT5i, Alone and in Combination with Other Therapies in MTAP-deleted NSCLC
1个月前
已关闭
USP1 inhibition: A journey from target discovery to clinical translation
1个月前
已完结
Clinical Pharmacokinetics and Pharmacodynamics of Cabozantinib
1个月前
已完结
Myeloid-derived suppressor cells in cancer and cancer therapy
2个月前
已完结
皖公网安备34019202002308
